Last week saw two significant announcements from the life sciences business developing products to tackle obesity, high cholesterol and diabetes. The first was a joint development agreement with one of the world’s leading suppliers of food ingredients such as vitamins and nutritional lipids. Total revenues for Netherlands based Royal DSM in 2015 were €8.9bn. The agreement will allow for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic® no
12 Apr 2016
Scientific and commercial progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Scientific and commercial progress
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
12 Apr 2016 -
Author:
Derren Nathan -
Pages:
7
Last week saw two significant announcements from the life sciences business developing products to tackle obesity, high cholesterol and diabetes. The first was a joint development agreement with one of the world’s leading suppliers of food ingredients such as vitamins and nutritional lipids. Total revenues for Netherlands based Royal DSM in 2015 were €8.9bn. The agreement will allow for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic® no